AIDS Therapies (3TC)

Epivir Approved in European Union

Published in AIDS Weekly, August 26th, 1996

BioChem Pharma Inc., Laval, Quebec, Canada, announced that the European Medicines Evaluation Agency (EMEA) has approved the application to market Epivir (3TC) in the 15 member states of the European Union (EU) to treat HIV/AIDS.

This follows the recommendation of the EU's scientific advisory committee, the Committee for Proprietary Medicinal Products, which voted on April 18, 1996, in favor of the approval of Epivir. In the European Union, Epivir is indicated in combination with other antiretroviral agents for the treatment of HIV infected adults and children of 12 years of age and over, with progressive immunodeficiency (CD4 counts of 500 cells/mm³ or...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (1996-08-26)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry